FusionPlex® Dx is an RNA-based targeted gene panel for detecting biomarkers implicated in the most prevalent solid tumors, especially non-small cell lung cancer (NSCLC). The panel covers ESMO-recommended targets including MET, NTRK1-3, ALK, ROS1, and RET, in addition to pan-tumor comprehensive genomic profiling, and provides highly actionable and quick therapy guidance. Coverage also includes 41 analytical biomarkers, such as FGFR1-3 and NRG1, plus additional key biomarkers to advance precision oncology by providing broader therapy options and optimal clinical trial enrollment. The panel is validated for use on Illumina® MiSeqDx and Illumina NextSeq 550Dx sequencers. It is powered by Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions in a single sequencing product, even without prior knowledge of fusion partners or breakpoints.
This approach leverages DNA, RNA or ctDNA input types for sensitive characterization of all variant types from low-input clinical research samples.
MP RNA-based assays detect both known and novel fusion and can help you identify more patients who may be eligible for fusion-directed therapies.
Superior Fusion Detection for Better Therapy Selection
Get complete information from your low-input FFPE sample - detect fusions, copy number variations (CNVs), single-nucleotide variant (SNVs), insertions and deletions (indels), RNA expression levels, and microsatellite instability (MSI) status.
Scalable and Flexible
Adaptable to flexible laboratory throughput and validated on MiseqDx and NextSeq 550Dx instruments.
Quick and Simple Workflow
Easy-to-handle lyophilized reagents and a simple workflow minimize errors and reduce turnaround time for better routine testing.